Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics Limited has disclosed a notice from Regal Funds Management Asia Pte Limited in compliance with the Australian Takeovers Panel Guidance Note 20 on Equity Derivatives. This disclosure involves long equity derivative positions related to Alterity’s securities, highlighting a significant stake held by the investment manager, which may impact the company’s market perception and investor relations.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. The company is listed on both the Australian Securities Exchange (ASX) and NASDAQ, indicating a broad market focus.
Average Trading Volume: 13,832,480
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
See more data about ATH stock on TipRanks’ Stock Analysis page.